LoDoCo
Trial question
What is the role of low-dose colchicine in patients with clinically stable coronary disease?
Study design
Multi-center
Open label
RCT
Population
Characteristics of study participants
11.0% female
89.0% male
N = 532
532 patients (59 female, 473 male)
Inclusion criteria: patients with stable coronary disease receiving aspirin and/or clopidogrel and statins
Key exclusion criteria: contraindication to colchicine, history of bypass surgery < 10 years ago, unwilling to provide consent, or major competing comorbidities
Interventions
N=282 colchicine (0.5 mg/day)
N=250 control (no colchicine)
Primary outcome
Acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke
5.3
16
16.0 %
12.0 %
8.0 %
4.0 %
0.0 %
Colchicine
Control
Significant
decrease ▼
NNT = 9
Significant decrease in acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke (5.3% vs. 16%; HR 0.33, 95% CI 0.18 to 0.59)
Secondary outcomes
Significant decrease in acute coronary syndrome (4.6% vs. 13.6%; HR 0.33, 95% CI 0.18 to 0.63)
Significant decrease in Acute coronary syndrome nonstent-related (3.2% vs. 12%; HR 0.26, 95% CI 0.12 to 0.55)
Significant decrease in nonstent-related acute myocardial infarction (1.6% vs. 5.6%; HR 0.25, 95% CI 0.08 to 0.76)
Conclusion
In patients with stable coronary disease receiving aspirin and/or clopidogrel and statins, colchicine was superior to control with respect to acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke.
Reference
Nidorf SM, Eikelboom JW, Budgeon CA et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410.
Open reference URL